Law360, New York (April 08, 2009, 12:00 AM ET) -- Mylan Pharmaceuticals Inc. and Schering Corp. have reached an agreement in patent litigation over Clarinex that will allow the generics maker to begin selling a copycat version of the allergy medicine in July 2012.
The agreement allowing Mylan to make desloratadine in 5 mg tablets resolves all claims pending between the two pharmaceutical rivals in the U.S. District Court for the District of New Jersey, the companies said Wednesday.
Mylan will have the right to market the tablets in the U.S. on July 1, 2012, or...
Schering, Mylan Settle Generic Clarinex Patent Case
To view the full article, take a free trial now.
